The use of stem cells for the repair of cardiac tissue in ischemic heart disease

References

• Tendera M. How much does Europe invest in the treatment of cardiovascular diseases? Eur. Heart J.27(13), 1521–1522 (2006).
   PubMed Web of Science ®Google Scholar
• Conley BJ, Young JC, Trounson AO, Mollard R. Derivation, propagation and differentiation of human embryonic stem cells. Int. J. Biochem. Cell Biol.36(4), 555–567 (2004).
   PubMed Web of Science ®Google Scholar
• Mummery C, Ward D, van den Brink CE et al. Cardiomyocyte differentiation of mouse and human embryonic stem cells. J. Anat.200(Pt 3), 233–242 (2002).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5), 861–872 (2007).
   PubMed Web of Science ®Google Scholar
• Guan K, Nayernia K, Maier LS et al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature440(7088), 1199–1203 (2006).
   PubMed Web of Science ®Google Scholar
• Shao H, Wei Z, Wang L et al. Generation and characterization of mouse parthenogenetic embryonic stem cells containing genomes from non-growing and fully grown oocytes. Cell Biol. Int.31(11), 1336–1344 (2007).
   PubMed Web of Science ®Google Scholar
• Kaji K, Norrby K, Paca A, Mileikovsky M, Mohseni P, Woltjen K. Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature458(7239), 771–775 (2009).
   PubMed Web of Science ®Google Scholar
• Srivastava D, Ivey KN. Potential of stem-cell-based therapies for heart disease. Nature441(7097), 1097–1099 (2006).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell126(4), 663–676 (2006)
   PubMed Web of Science ®Google Scholar
• Kitajima S, Takagi A, Inoue T, Saga Y. MesP1 and MesP2 are essential for the development of cardiac mesoderm. Development127(15), 3215–3226 (2000).
   PubMed Web of Science ®Google Scholar
• Saga Y, Kitajima S, Miyagawa-Tomita S. Mesp1 expression is the earliest sign of cardiovascular development. Trends Cardiovasc. Med.10(8), 345–352 (2000).
   PubMed Web of Science ®Google Scholar
• David R, Brenner C, Stieber J et al. MesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling. Nat. Cell Biol.10(3), 338–345 (2008).
   PubMed Web of Science ®Google Scholar
• David R, Stieber J, Fischer E et al. Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. Cardiovasc. Res.84(2), 263–272 (2009).
   PubMed Web of Science ®Google Scholar
• David R, Theiss H, Franz WM. Connexin 40 promoter-based enrichment of embryonic stem cell-derived cardiovascular progenitor cells. Cells Tissues Organs188(1–2), 62–69 (2008).
   PubMed Web of Science ®Google Scholar
• Müller M, Fleischmann BK, Selbert S et al. Selection of ventricular-like cardiomyocytes from ES cells in vitro.FASEB J.14(15), 2540–2548. (2000).
   PubMed Web of Science ®Google Scholar
• Zweigerdt R, Burg M, Willbold E, Abts H, Ruediger M. Generation of confluent cardiomyocyte monolayers derived from embryonic stem cells in suspension: a cell source for new therapies and screening strategies. Cytotherapy5(5), 399–413 (2003).
   PubMed Web of Science ®Google Scholar
• Xu XQ, Graichen R, Soo SY et al. Chemically defined medium supporting cardiomyocyte differentiation of human embryonic stem cells. Differentiation76(9), 958–970 (2008).
   PubMed Web of Science ®Google Scholar
• Lee MS, Makkar RR. Stem-cell transplantation in myocardial infarction: a status report. Ann. Intern. Med.140(9), 729–737 (2004).
   PubMed Web of Science ®Google Scholar
• Cooke MJ, Stojkovic M, Przyborski SA. Growth of teratomas derived from human pluripotent stem cells is influenced by the graft site. Stem Cells Dev.15(2), 254–259 (2006).
   PubMed Web of Science ®Google Scholar
• Xue T, Cho HC, Akar FG et al. Functional integration of electrically active cardiac derivatives from genetically engineered human embryonic stem cells with quiescent recipient ventricular cardiomyocytes: insights into the development of cell-based pacemakers. Circulation111(1), 11–20 (2005).
   PubMed Web of Science ®Google Scholar
• Grepin C, Nemer G, Nemer M. Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development124(12), 2387–2395 (1997).
   PubMed Web of Science ®Google Scholar
• Singh AM, Li FQ, Hamazaki T, Kasahara H, Takemaru KI, Terada N. Chibby, an antagonist of the Wnt/β-catenin pathway, facilitates cardiomyocyte differentiation of murine embryonic stem cells. Circulation115(5), 617–626 (2007).
   PubMed Web of Science ®Google Scholar
• David R, Groebner M, Franz WM. Magnetic cell sorting purification of differentiated embryonic stem cells stably expressing truncated human CD4 as surface marker. Stem Cells23(4), 477–482 (2005).
   PubMed Web of Science ®Google Scholar
• Gassanov N, Er F, Zagidullin N, Hoppe UC. Endothelin induces differentiation of ANP–EGFP expressing embryonic stem cells towards a pacemaker phenotype. FASEB J.18(14), 1710–1712 (2004).
   PubMed Web of Science ®Google Scholar
• Zandstra PW, Bauwens C, Yin T et al. Scalable production of embryonic stem cell-derived cardiomyocytes. Tissue Eng.9(4), 767–778 (2003).
   PubMedGoogle Scholar
• Okita K, Yamanaka S. Induction of pluripotency by defined factors. Exp. Cell Res.316(16), 2565–2570 (2010).
   PubMed Web of Science ®Google Scholar
• Zimmermann WH, Schneiderbanger K, Schubert P et al. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res.90(2), 223–230 (2002).
   PubMed Web of Science ®Google Scholar
• Radisic M, Marsano A, Maidhof R, Wang Y, Vunjak-Novakovic G. Cardiac tissue engineering using perfusion bioreactor systems. Nat. Protoc.3(4), 719–738 (2008).
   PubMed Web of Science ®Google Scholar
• Zhao YS, Wang CY, Li DX et al. Construction of a unidirectionally beating 3-dimensional cardiac muscle construct. J. Heart Lung Transplant.24(8), 1091–1097 (2005).
   PubMed Web of Science ®Google Scholar
• Tuzlakoglu K, Reis RL. Biodegradable polymeric fiber structures in tissue engineering. Tissue Eng. Part B Rev.15(1), 17–27 (2009).
   PubMed Web of Science ®Google Scholar
• Zakharova L, Mastroeni D, Mutlu N et al. Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc. Res.87(1), 40–49 (2010).
   PubMed Web of Science ®Google Scholar
• Wu KH, Mo XM, Liu YL. Cell sheet engineering for the injured heart. Med. Hypotheses71(5), 700–702 (2008).
   PubMed Web of Science ®Google Scholar
• Zimmermann WH, Melnychenko I, Wasmeier G et al. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med.12(4), 452–458 (2006).
   PubMed Web of Science ®Google Scholar
• Masuda S, Shimizu T, Yamato M, Okano T. Cell sheet engineering for heart tissue repair. Adv. Drug Deliv. Rev.60(2), 277–285 (2008).
   PubMed Web of Science ®Google Scholar
• Ott HC, Matthiesen TS, Goh SK et al. Perfusion-decellularized matrix: using nature’s platform to engineer a bioartificial heart. Nat. Med.14(2), 213–221 (2008).
   PubMed Web of Science ®Google Scholar
• Deindl E, Zaruba MM, Brunner S et al. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J.20(7), 956–958 (2006).
   PubMed Web of Science ®Google Scholar
• Ince H, Petzsch M, Kleine HD et al. Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) trial. Circulation112(9 Suppl.), I73–80 (2005).
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S, Bodine DM, Leri A, Anversa P. Transplanted adult bone marrow cells repair myocardial infarcts in mice. Ann. NY Acad. Sci.938, 221–229 (2001).
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature410(6829), 701–705 (2001).
   PubMed Web of Science ®Google Scholar
• Schächinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1210–1221 (2006).
   PubMed Web of Science ®Google Scholar
• Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet364(9429), 141–148 (2004).
   PubMed Web of Science ®Google Scholar
• Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature428(6983), 664–668 (2004).
   PubMed Web of Science ®Google Scholar
• Nygren JM, Jovinge S, Breitbach M et al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat. Med.10(5), 494–501 (2004).
   PubMed Web of Science ®Google Scholar
• Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature428(6983), 668–673 (2004).
   PubMed Web of Science ®Google Scholar
• Zaruba MM, Huber BC, Brunner S et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc. Res.77(4), 722–731 (2008).
   PubMed Web of Science ®Google Scholar
• Zaruba MM, Theiss HD, Vallaster M et al. Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. Cell Stem Cell4(4), 313–323 (2009).
   PubMed Web of Science ®Google Scholar
• Henning RJ, Aufman J, Shariff M et al. Human umbilical cord blood mononuclear cells decrease fibrosis and increase cardiac function in cardiomyopathy. Regen. Med.5(1), 45–54 (2010).
   PubMed Web of Science ®Google Scholar
• Sodian R, Schaefermeier P, Abegg-Zips S et al. Use of human umbilical cord blood-derived progenitor cells for tissue-engineered heart valves. Ann. Thorac. Surg.89(3), 819–828 (2010).
   PubMed Web of Science ®Google Scholar
• Ince H, Petzsch M, Rehders TC, Chatterjee T, Nienaber CA. Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J. Endovasc. Ther.11(6), 695–704 (2004).
   PubMed Web of Science ®Google Scholar
• Smits PC, van Geuns RJ, Poldermans D et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J. Am. Coll. Cardiol.42(12), 2063–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Siminiak T, Fiszer D, Jerzykowska O et al. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur. Heart J.26(12), 1188–1195 (2005).
   PubMed Web of Science ®Google Scholar
• Herreros J, Prosper F, Perez A et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur. Heart J.24(22), 2012–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Menasche P, Hagege AA, Vilquin JT et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol.41(7), 1078–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. Am. Heart J.148(3), 531–537 (2004).
   PubMed Web of Science ®Google Scholar
• Menasche P, Alfieri O, Janssens S et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation117(9), 1189–1200 (2008).
   PubMed Web of Science ®Google Scholar
• Pagani FD, DerSimonian H, Zawadzka A et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J. Am. Coll. Cardiol.41(5), 879–888 (2003).
   PubMed Web of Science ®Google Scholar
• Formigli L, Zecchi-Orlandini S, Meacci E, Bani D. Skeletal myoblasts for heart regeneration and repair: state of the art and perspectives on the mechanisms for functional cardiac benefits. Curr. Pharm. Des.16(8), 915–928 (2010).
   PubMed Web of Science ®Google Scholar
• Chamuleau SA, Vrijsen KR, Rokosh DG, Tang XL, Piek JJ, Bolli R. Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells. Neth. Heart J.17(5), 199–207 (2009).
   PubMed Web of Science ®Google Scholar
• Johnston PV, Sasano T, Mills K et al. Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation120(12), 1075–1083 (2009).
   PubMed Web of Science ®Google Scholar
• Smith RR, Barile L, Cho HC et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation115(7), 896–908 (2007).
   PubMed Web of Science ®Google Scholar
• Davis DR, Zhang Y, Smith RR et al. Validation of the cardiosphere method to culture cardiac progenitor cells from myocardial tissue. PLoS One4(9), e7195 (2009).
   PubMedGoogle Scholar
• Chimenti I, Smith RR, Li TS et al. Relative roles of direct regeneration versus paracrine effects of human cardiosphere-derived cells transplanted into infarcted mice. Circ. Res.106(5), 971–980 (2010).
   PubMed Web of Science ®Google Scholar
• Tang XL, Rokosh G, Sanganalmath SK et al. Intracoronary administration of cardiac progenitor cells alleviates left ventricular dysfunction in rats with a 30-day-old infarction. Circulation121(2), 293–305 (2010).
   PubMed Web of Science ®Google Scholar
• Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur. Heart J.30(24), 2978–2984 (2009).
   PubMed Web of Science ®Google Scholar
• Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (Bone Marrow Transfer to Enhance ST-elevation Infarct Regeneration) trial. Circulation113(10), 1287–1294 (2006).
   PubMed Web of Science ®Google Scholar
• Dill T, Schächinger V, Rolf A et al. Intracoronary administration of bone marrow-derived progenitor cells improves left ventricular function in patients at risk for adverse remodeling after acute ST-segment elevation myocardial infarction: results of the Reinfusion of Enriched Progenitor cells and Infarct Remodeling in Acute Myocardial Infarction study (REPAIR-AMI) cardiac magnetic resonance imaging substudy. Am. Heart J.157(3), 541–547 (2009).
   PubMed Web of Science ®Google Scholar
• Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol.94(1), 92–95 (2004).
   PubMed Web of Science ®Google Scholar
• Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J.28(6), 766–772 (2007).
   PubMed Web of Science ®Google Scholar
• Martin-Rendon E, Brunskill SJ, Hyde CJ, Stanworth SJ, Mathur A, Watt SM. Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review. Eur. Heart J.29(15), 1807–1818 (2008).
   PubMed Web of Science ®Google Scholar
• Thomas J, Liu F, Link DC. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr. Opin. Hematol.9(3), 183–189 (2002).
   PubMed Web of Science ®Google Scholar
• Engelmann MG, Theiss HD, Hennig-Theiss C et al. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J. Am. Coll. Cardiol.48(8), 1712–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Ripa RS, Jorgensen E, Wang Y et al. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation113(16), 1983–1992 (2006).
   PubMed Web of Science ®Google Scholar
• Zohlnhofer D, Ott I, Mehilli J et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA295(9), 1003–1010 (2006).
   PubMed Web of Science ®Google Scholar
• Zohlnhofer D, Dibra A, Koppara T et al. Stem cell mobilization by granulocyte colony-stimulating factor for myocardial recovery after acute myocardial infarction: a meta-analysis. J. Am. Coll. Cardiol.51(15), 1429–1437 (2008).
   PubMed Web of Science ®Google Scholar
• Kim HK, De La Luz Sierra M, Williams CK, Gulino AV, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood108(3), 812–820 (2006).
   PubMed Web of Science ®Google Scholar
• Levesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest.111(2), 187–196 (2003).
   PubMed Web of Science ®Google Scholar
• Petit I, Szyper-Kravitz M, Nagler A et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat. Immunol.3(7), 687–694 (2002).
   PubMed Web of Science ®Google Scholar
• Stein A, Zohlnhofer D, Pogatsa-Murray G et al. Expression of CXCR4, VLA-1, LFA-3 and transducer of ERB in G-CSF-mobilised progenitor cells in acute myocardial infarction. Thromb. Haemost.103(3), 638–643 (2010).
   PubMed Web of Science ®Google Scholar
• Brunner S, Winogradow J, Huber BC et al. Erythropoietin administration after myocardial infarction in mice attenuates ischemic cardiomyopathy associated with enhanced homing of bone marrow-derived progenitor cells via the CXCR-4/SDF-1 axis. FASEB J.23(2), 351–361 (2009).
   PubMed Web of Science ®Google Scholar
• Theiss HD, Brenner C, Engelmann MG et al. Safety and efficacy of Sitagliptin plus Granulocyte-Colony-Stimulating Factor in Patients Suffering from Acute Myocardial Infarction (SITAGRAMI-trial) – rationale, design and first interim analysis. Int. J. Cardiol.145(2), 282–284 (2010).
   PubMed Web of Science ®Google Scholar
• Korf-Klingebiel M, Kempf T, Sauer T et al. Bone marrow cells are a rich source of growth factors and cytokines: implications for cell therapy trials after myocardial infarction. Eur. Heart J.29(23), 2851–2858 (2008).
   PubMed Web of Science ®Google Scholar
• Fazel S, Cimini M, Chen L et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J. Clin. Invest.116(7), 1865–1877 (2006).
   PubMed Web of Science ®Google Scholar
• Saxena A, Fish JE, White MD et al. Stromal cell-derived factor-1α is cardioprotective after myocardial infarction. Circulation117(17), 2224–2231 (2008).
   PubMed Web of Science ®Google Scholar
• Srivastava D, Saxena A, Michael Dimaio J, Bock-Marquette I. Thymosin β4 is cardioprotective after myocardial infarction. Ann. NY Acad. Sci.1112, 161–170 (2007).
   PubMed Web of Science ®Google Scholar
• Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc. Natl Acad. Sci. USA106(29), 12103–12108 (2009).
   PubMed Web of Science ®Google Scholar
• Liu N, Bezprozvannaya S, Williams AH et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev.22(23), 3242–3254 (2008).
   PubMed Web of Science ®Google Scholar
• Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature456(7224), 980–984 (2008).
   PubMed Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Liu N et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc. Natl Acad. Sci. USA103(48), 18255–18260 (2006).
   PubMed Web of Science ®Google Scholar
• Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev. Cell11(5), 723–732 (2006).
   PubMed Web of Science ®Google Scholar
• Van Hoof D, Dormeyer W, Braam SR et al. Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. J. Proteome Res.9(3), 1610–1618 (2010).
   PubMed Web of Science ®Google Scholar
• Wobus AM, Kaomei G, Shan J et al. Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J. Mol. Cell Cardiol.29(6), 1525–1539. (1997).
   PubMed Web of Science ®Google Scholar
• Paquin J, Danalache BA, Jankowski M, McCann SM, Gutkowska J. Oxytocin induces differentiation of P19 embryonic stem cells to cardiomyocytes. Proc. Natl Acad. Sci. USA99(14), 9550–9555 (2002).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Lord B, Schulze PC et al. Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation107(14), 1912–1916 (2003).
   PubMed Web of Science ®Google Scholar
• Ventura C, Maioli M, Asara Y et al. Butyric and retinoic mixed ester of hyaluronan. A novel differentiating glycoconjugate affording a high throughput of cardiogenesis in embryonic stem cells. J. Biol. Chem.279(22), 23574–23579 (2004).
   PubMed Web of Science ®Google Scholar
• Ventura C, Maioli M, Asara Y et al. Turning on stem cell cardiogenesis with extremely low frequency magnetic fields. FASEB J.19(1), 155–157 (2005).
   PubMed Web of Science ®Google Scholar
• Yuasa S, Itabashi Y, Koshimizu U et al. Transient inhibition of BMP signaling by Noggin induces cardiomyocyte differentiation of mouse embryonic stem cells. Nat. Biotechnol.23(5), 607–611 (2005).
   PubMed Web of Science ®Google Scholar
• Roggia C, Ukena C, Bohm M, Kilter H. Hepatocyte growth factor (HGF) enhances cardiac commitment of differentiating embryonic stem cells by activating PI3 kinase. Exp. Cell Res.313(5), 921–930 (2006).
   PubMed Web of Science ®Google Scholar
• Mummery CL, Ward D, Passier R. Differentiation of human embryonic stem cells to cardiomyocytes by coculture with endoderm in serum-free medium. Curr. Protoc. Stem. Cell Biol. Chapter 1, Unit 1F.2 (2007).
   PubMedGoogle Scholar
• Graichen R, Xu X, Braam SR et al. Enhanced cardiomyogenesis of human embryonic stem cells by a small molecular inhibitor of p38 MAPK. Differentiation76(4), 357–370 (2008).
   PubMed Web of Science ®Google Scholar
• Yang L, Soonpaa MH, Adler ED et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature453(7194), 524–528 (2008).
   PubMed Web of Science ®Google Scholar
• Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet367(9505), 113–121 (2006).
   PubMed Web of Science ®Google Scholar
• Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1199–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Tendera M, Wojakowski W, Ruzyllo W et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) trial. Eur. Heart J.30(11), 1313–1321 (2009).
   PubMed Web of Science ®Google Scholar
• Gyongyosi M, Lang I, Dettke M et al. Combined delivery approach of bone marrow mononuclear stem cells early and late after myocardial infarction: the MYSTAR prospective, randomized study. Nat. Clin. Pract. Cardiovasc. Med.6(1), 70–81 (2009).
   PubMedGoogle Scholar
• Surder D, Schwitter J, Moccetti T et al. Cell-based therapy for myocardial repair in patients with acute myocardial infarction: rationale and study design of the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI). Am. Heart J.160(1), 58–64 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao Y, Ransom JF, Li A et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1–2. Cell129(2), 303–317 (2007).
   PubMed Web of Science ®Google Scholar
• Maurer B, Stanczyk J, Jungel A et al. miR-29 is a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum.62(6), 1733–1743 (2010).
   PubMed Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Thatcher JE et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc. Natl Acad. Sci. USA105(35), 13027–13032 (2008).
   PubMed Web of Science ®Google Scholar
• Wang S, Aurora AB, Johnson BA et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev. Cell15(2), 261–271 (2008).
   PubMed Web of Science ®Google Scholar
• Wang S, Olson EN. AngiomiRs – key regulators of angiogenesis. Curr. Opin. Genet. Dev.19(3), 205–211 (2009).
   PubMed Web of Science ®Google Scholar
• Li Q, Lin X, Yang X, Chang J. NFATc4 is negatively regulated in miR-133a-mediated cardiomyocyte hypertrophic repression. Am. J. Physiol. Heart Circ. Physiol.298(5), H1340–H1347 (2010).
   PubMed Web of Science ®Google Scholar
• Gonsalves CS, Kalra VK. Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1α and NF-κB and microRNAs 135a and 199a-5p. J. Immunol.184(7), 3878–3888 (2010).
   PubMed Web of Science ®Google Scholar
• Rane S, He M, Sayed D et al. Downregulation of miR-199a derepresses hypoxia-inducible factor-1α and sirtuin 1 and recapitulates hypoxia preconditioning in cardiac myocytes. Circ. Res.104(7), 879–886 (2009).
   PubMed Web of Science ®Google Scholar
• Callis TE, Pandya K, Seok HY et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J. Clin. Invest.119(9), 2772–2786 (2009).
   PubMed Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science316(5824), 575–579 (2007).
   PubMed Web of Science ®Google Scholar
• Ren XP, Wu J, Wang X et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation119(17), 2357–2366 (2009).
   PubMed Web of Science ®Google Scholar